Daiichi Life Insurance Co. Ltd. Makes New Investment in Edwards Lifesciences Corporation $EW

Daiichi Life Insurance Co. Ltd. purchased a new stake in Edwards Lifesciences Corporation (NYSE:EW) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 22,329 shares of the medical research company’s stock, valued at approximately $2,020,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. TrinityBridge Ltd bought a new stake in shares of Edwards Lifesciences during the second quarter valued at approximately $27,000. MV Capital Management Inc. acquired a new stake in Edwards Lifesciences in the 4th quarter valued at $26,000. Hanson & Doremus Investment Management acquired a new stake in Edwards Lifesciences in the 1st quarter valued at $25,000. Kemnay Advisory Services Inc. bought a new stake in shares of Edwards Lifesciences during the fourth quarter worth about $27,000. Finally, JPL Wealth Management LLC bought a new stake in Edwards Lifesciences during the 3rd quarter worth approximately $25,000. Institutional investors own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on EW shares. JPMorgan Chase & Co. increased their target price on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “overweight” rating in a report on Friday, July 24th. Barclays reaffirmed an “overweight” rating and set a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Evercore reaffirmed an “outperform” rating and issued a $100.00 price objective on shares of Edwards Lifesciences in a report on Monday, July 6th. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. Finally, Piper Sandler reissued an “overweight” rating and set a $101.00 target price (up from $100.00) on shares of Edwards Lifesciences in a report on Friday, July 24th. Seventeen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $100.27.

Edwards Lifesciences Trading Up 0.1%

Shares of EW opened at $89.89 on Monday. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $96.29. The stock has a market cap of $51.76 billion, a PE ratio of 51.66, a P/E/G ratio of 2.25 and a beta of 0.85. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The business’s 50-day moving average price is $89.21 and its 200-day moving average price is $84.68.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The company had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. During the same quarter last year, the company earned $0.67 earnings per share. The firm’s quarterly revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, equities analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the transaction, the vice president owned 98,611 shares of the company’s stock, valued at approximately $8,521,962.62. This trade represents a 19.01% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Andrew M. Dahl sold 568 shares of the firm’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the transaction, the senior vice president directly owned 15,334 shares in the company, valued at $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 25,570 shares of company stock worth $2,219,390. 0.31% of the stock is currently owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.